![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page1211.jpg)
220 patients – 9 institutions
60 Gy + TMZ + 72 Gy/2,4 Gy
IMRT SIB guided by MR spectroscopy
Global survival
MRI + spectro /2months
Randomization
MRI + spectro
60 Gy + TMZ
SPECTRO GLIO
Newly Diagnosed Glioblastoma
Prospective multicentric phase III trial
Promoted by Institut Claudius Regaud– financed by French national cancer institute
MR spectroscopic imaging for dose-painting
21